X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AJANTA PHARMA ALEMBIC PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 28.9 24.0 120.2% View Chart
P/BV x 6.6 9.9 66.5% View Chart
Dividend Yield % 0.7 0.6 118.0%  

Financials

 ALEMBIC PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
AJANTA PHARMA
Mar-16
ALEMBIC PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs7921,720 46.0%   
Low Rs4431,103 40.2%   
Sales per share (Unadj.) Rs167.0194.6 85.8%  
Earnings per share (Unadj.) Rs38.245.2 84.4%  
Cash flow per share (Unadj.) Rs42.050.3 83.5%  
Dividends per share (Unadj.) Rs4.008.00 50.0%  
Dividend yield (eoy) %0.60.6 114.3%  
Book value per share (Unadj.) Rs84.9132.0 64.3%  
Shares outstanding (eoy) m188.5288.77 212.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.77.3 51.0%   
Avg P/E ratio x16.231.2 51.8%  
P/CF ratio (eoy) x14.728.1 52.4%  
Price / Book Value ratio x7.310.7 68.0%  
Dividend payout %10.517.7 59.2%   
Avg Mkt Cap Rs m116,383125,299 92.9%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2142,570 164.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,48717,275 182.3%  
Other income Rs m55166 33.1%   
Total revenues Rs m31,54217,442 180.8%   
Gross profit Rs m10,0605,807 173.2%  
Depreciation Rs m722451 160.3%   
Interest Rs m3749 75.3%   
Profit before tax Rs m9,3565,474 170.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,460 148.0%   
Profit after tax Rs m7,1944,014 179.2%  
Gross profit margin %31.933.6 95.0%  
Effective tax rate %23.126.7 86.6%   
Net profit margin %22.823.2 98.3%  
BALANCE SHEET DATA
Current assets Rs m15,0667,639 197.2%   
Current liabilities Rs m7,6742,715 282.7%   
Net working cap to sales %23.528.5 82.4%  
Current ratio x2.02.8 69.8%  
Inventory Days Days6743 154.9%  
Debtors Days Days4179 51.6%  
Net fixed assets Rs m8,2376,914 119.1%   
Share capital Rs m377177 213.1%   
"Free" reserves Rs m15,41611,442 134.7%   
Net worth Rs m16,00511,721 136.6%   
Long term debt Rs m0149 0.0%   
Total assets Rs m24,59414,814 166.0%  
Interest coverage x255.2112.9 226.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.31.2 109.8%   
Return on assets %29.427.4 107.2%  
Return on equity %44.934.2 131.2%  
Return on capital %58.746.5 126.1%  
Exports to sales %55.755.1 101.1%   
Imports to sales %10.46.0 173.6%   
Exports (fob) Rs m17,5519,527 184.2%   
Imports (cif) Rs m3,2831,038 316.4%   
Fx inflow Rs m17,81110,422 170.9%   
Fx outflow Rs m5,3181,678 316.9%   
Net fx Rs m12,4938,744 142.9%   
CASH FLOW
From Operations Rs m9,3043,264 285.1%  
From Investments Rs m-3,105-2,093 148.3%  
From Financial Activity Rs m-1,959-1,186 165.2%  
Net Cashflow Rs m4,240-15 -28,648.6%  

Share Holding

Indian Promoters % 74.1 73.8 100.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 1.6 187.1%  
FIIs % 9.1 7.6 119.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.0 81.8%  
Shareholders   49,328 20,968 235.3%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 21, 2018 11:45 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS